Oncogenic genes and human malignancy. by Lebowitz, P.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 56 (1983), 121-129
Oncogenic Genes and Human Malignancy
PAUL LEBOWITZ, M.D.
Department ofInternal Medicine and Division of Oncology, Comprehensive
Cancer Center, Yale University School ofMedicine, New Haven, Connecticut
Received April 19, 1983
All vertebrates possess a series of genes which are homologs of the oncogenic genes of acute
transforming retroviruses. Two lines of evidence suggest that these genes may play a role in the
development of human malignancy: (1) DNA from a variety of human tumors transforms NIH
3T3 mouse fibroblasts and the transforming genes from a number of carcinomas, sarcomas,
and hematological malignancies have been identified as members of a family of genes, the ras
family, closely related to the oncogenic genes of the Harvey and Kirsten murine sarcoma
viruses; and (2) correlations exist between the chromosomal localizations of certain oncogenes
and the chromosomal breakpoints in specific translocations and deletions in certain human
malignancies. In three separate hematological malignancies, alterations in more than one on-
cogenic gene may be involved in the neoplastic process.
For many years our thinking about the etiology of malignancy has rested on two
basic concepts. The most fundamental is that the malignant process probably in-
volves multiple events: an initial change which makes a cell permissive for under-
going transformation to the malignant phenotype; the actual transformation, or
oncogenic, event; and a series of subsequent steps which allow the malignancy to
survive in the host, determine the specific phenotype ofthe transformed cell, and ex-
plain, at least in part, the diverse clinical behavior of seemingly similar malignancies
in different individuals. The second basic concept is that the transformation step
and probably all three steps leading to malignancy result from mutations or other
alterations in cellular DNA.
Our understanding ofthe etiology ofmalignancy has taken a great leap forward in
the past few years with the discoveries that the human genome contains specific
genes which are potentially oncogenic and that these genes (oncogenes or onc genes)
are homologs of the oncogenic genes of a number of RNA tumor viruses
(retroviruses). Furthermore, recent studies suggest that mutations in or trans-
locations or deletions of some of these genes may play a role in the development of
certain human malignancies.
RETROVIRAL AND HUMAN ONCOGENIC GENES
Retroviruses are the etiological agents of a wide variety of spontaneous and in-
duced malignancies of animals. These viruses fall into two broad groups: those that
cause malignancy over months (chronic acting viruses, mostly leukemia viruses) and
those that lead to malignancy within weeks (acute leukemia, lymphoma, sarcoma,
and carcinoma viruses). Whereas members of the former group possess gag, env,
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All rights of reproduction in aniy form reserved.and pol genes (coding respectively for viral core and coat proteins and reverse
transcriptase) which confer replication competence, members of the latter (except
for RSV') contain large deletions in or lack one or more of these genes and are
replication-defective. In place of the deleted sequences, and in RSV in addition to
the replicatory genes, the acute acting viruses contain oncogenic genes which confer
upon them the ability to cause acute malignancies in animals and transform
fibroblasts and in some cases hematological precursors in tissue culture [1-3]. To
date, about twenty acute acting viruses have been isolated. The oncogenic gene of
each codes for an oncogenic protein (AEV is the sole exception, containing two
separate oncogenes coding for two separate oncogenic proteins). On the basis of the
following properties, four types of oncogenic proteins have been distinguished: the
proteins of several avian sarcoma viruses (e.g., RSV), FeSV and AbLV, all of which
bind to the inner aspect ofthe plasma membrane oftransformed cells, serve as ATP-
dependent protein kinases, and phosphorylate both their own tyrosine residues and
those of certain cellular proteins [1,2]; the structurally similar ras proteins of Ha-
and KiSV which are 21,000 daltons, also are associated with the inner aspect of the
plasma membrane of transformed cells, but bind GTP and GDP rather than adenine
nucleotides and appear only to autophosphorylate one of their own threonine
residues [4]; the myc protein of AMV which is a nuclear protein with DNA-binding
activity [5]; and the erb B protein ofAEV which is a cytoplasmic glycoprotein [1,2].
Despite this information, the mechanism(s) by which these proteins induce
malignancy remains unknown.
In the past few years DNA sequences bearing extensive homology to retrovirus
oncogenes have been identified in cells from a wide variety of vertebrates, including
man [1,2,6]. Furthermore, certain of the cellular homologs of viral oncogenes are
active, serving as templates for synthesis ofproteins that share immunological deter-
minants with and are similar in size and, in certain cases, sequence to the respective
viral oncogenic proteins [1,2]. These findings have a number of important implica-
tions. (1) They suggest a cellular origin for the oncogenes ofthe acute acting viruses.
Moreover, it seems likely that these viruses arose by recombinational events between
chronic acting viruses and cellular oncogenic sequences. (2) The facts that cellular
genes are highly conserved and that some are active suggest that they carry out im-
portant functions in normal cells. Indeed, there is some evidence to suggest that cer-
tain oncogenes may be involved in regulation of cell differentiation [7]. (3) The
similarity of viral oncogenic proteins and their cellular counterparts taken together
with the observation that virus-transformed cells express elevated levels of viral on-
cogenic proteins [1,2] raises the question if malignancy in the absence ofviral infec-
tion may at least in some cases result from elevated levels ofthe cellular counterparts
of viral oncogenic proteins, i.e., of normal cellular proteins. (4) Most important, the
data suggest that all normal vertebrate cells harbor potentially oncogenic sequences.
Indeed, cloned cellular homologs of the HaSV ras gene and the MoSV mos gene,
'Abbreviations for retroviruses and their oncogenic genes are as follows: Abelson murine leukemia
virus: AbLV and abi; Snyder-Theilen feline sarcoma virus: FeSV andfes; Moloney murine sarcoma virus:
MoSV and mos; avian erythroblastosis virus: AEV and erb A and B; avian myeloblastosis virus: AMV
and myb; avian myelocytomatosis virus, strain 29: MC29 and myc; Harvey murine sarcoma virus: HaSV
and rasHa; Kirsten murine sarcoma virus: KiSV and rasKi; simian sarcoma virus: SSV and sis; Rous avian
sarcoma virus: RSV and src; avian leukosis virus: ALV, no oncogenic gene.
Abbreviations for human malignancies: Burkitt lymphoma: BL; acute myelogenous, promyelocytic,
and lymphoblastic leukemias: AML, APL, and ALL; chronic myelogenous leukemia: CML.
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linked at their 5'-end to viral activator sequences, transform mouse fibroblasts in
culture [8,9].
HUMAN TRANSFORMING GENES (ACTIVATED ONCOGENIC GENES)
In contrast to the viral etiology of many animal malignancies, attempts to
elucidate a viral role in human malignancies have been relatively disappointing.
Despite intensive searches, viruses have been implicated in only four malignancies:
BL and nasopharyngeal carcinoma, in which infection with Epstein-Barr (EB) virus
is an important step in oncogenesis [10]; certain T cell lymphomas, in which a newly
discovered retrovirus appears to be the etiological agent [ 1,12]; and certain cases of
hepatocellular carcinoma occurring in patients who are chronic carriers of hepatitis
B virus and suffer from chronic active hepatitis [13,14].
In an attempt to elucidate the mechanism by which malignancies of man and
animals not associated with viruses might arise, Drs. Robert Weinberg and Geoffrey
Cooper set out to test the hypothesis that malignancies contain altered or activated
normal genes that are responsible for oncogenesis and can transmit the transformed
phenotype. This approach was based upon an extensive body of evidence indicating
that the cellular target of a wide variety of oncogenic agents is DNA and the possi-
bility that under certain conditions the cellular homologs of viral oncogenes might
become mutated or otherwise activated, setting off a chain of events leading to
malignancy. In 1979, Shih et al. [15] and in 1980 Cooper et al. [16] showed that
transfection of monolayers of NIH 3T3 mouse fibroblasts with high molecular
weight DNA extracted from chemically induced tumors of mice led to the develop-
ment of foci of morphologically transformed cells at greater than control rates.
Moreover, tests for virus in the tumors were negative and DNA from primary
transformants yielded secondary and tertiary transformants on further rounds of
transfection of 3T3 cells. Subsequently, the 3T3 cell assay has been used to test a
wide variety of animal and human malignancies and cell lines, derived from malig-
nant tissue, for transforming genes. The human malignancies whose DNA has
demonstrated transforming genes include carcinomas of the lung, colon, bladder,
gall bladder, pancreas, breast and ovaries, B and T cell lymphomas, acute myeloid
and lymphoid leukemias, neuroblastomas, and certain sarcomas [15,17-25]. The
presence of human sequences in secondary and tertiary transformants, which con-
tain only small amounts of the original transfecting DNA (usually only one gene),
has supported the conclusion that in each of these cases transformation resulted
from the acquisition of human transforming genes.
The transforming genes from certain of these malignancies have been identified
by nucleic acid hybridization analysis (Southern blot analysis) of either cloned
transforming genes or DNA from secondary or tertiary transformants. Transform-
ing genes from two bladder carcinoma cell lines (EJ and T24, both probably derived
from the same original tumor) have been identified as homologs of the rasHa gene
[26-28] whereas the transforming gene from one bladder carcinoma has been iden-
tified as the homolog of the rasKi gene [Barbacid M: personal communication].
Similarly, transforming genes from three lung carcinoma cell lines have been identi-
fied as homologs of the rasHa and rasKi genes [26,29,30]. In addition, single pancreatic
and gall bladder carcinomas have demonstrated rasKi transforming genes [Barbacid
M: personal communication]. Transforming genes from the remaining malignancies
have not shown homology to any viral oncogene probes under stringent hybridiza-
tion conditions. However, recent studies [29,31] have shown that the cloned
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hybridize to rasHa and rasKi genes under non-stringent conditions and to each other
under stringent conditions. Moreover, transforming genes from single colon car-
cinoma, fibrosarcoma, and BL cell lines and from leukemic cells from one patient
with AML bear homology to the cloned HL60 transforming gene [311. These results
suggest that the ras family of genes contains an additional related member,
designated rasN, and that the transforming genes in the above six malignancies are
rasN genes. It is striking that all human transforming genes identified to date belong
to the ras family. Whether this reflects a selection inherent in the 3T3 cell assay or
activation of these genes in a wide variety of malignancies is not known. It also
seems quite remarkable that more than one member of the ras family can serve as
the transforming gene in bladder, lung, and colon carcinomas. Thus, activation of
any one of the endogenous ras genes may be capable of initiating the oncogenic pro-
cess in these and, likely, other malignancies. Finally, the transforming genes of cer-
tain malignancies, e.g., breast and ovarian carcinomas and certain lymphomas, have
not demonstrated homology to any of the known oncogenes. It thus seems almost
certain that additional cellular oncogenes exist and will require identification in the
future.
Characterization of human transforming genes has been carried to the nucleotide
level in four cases: the rasHa genes of the EJ bladder carcinoma [32-34] and HS 242
lung carcinoma [30] cell lines, the rasKi gene of the Calu-l lung carcinoma [35], and
the rasN gene of the SK-N-SH neuroblastoma cell lines[36]. In the EJ and Calu-1 cell
lines, single point mutations in the twelfth codon of the rasHa and rasKi genes have
been identified whereas, in the HS 242 and SK-N-SH lines, point mutations in the
61st codon of the rasHa and rasN genes have beenfound. (Although the three cellular
ras genes differ to some extent in nucleotide sequence, they code for p21 ras proteins
with similar amino acid sequences, including glycine and glutamine in positions 12
and 61, respectively). It has been suggested that these mutations, resulting in single
amino acid substitutions in the respective ras proteins, are responsible not only for
the acquisition of transforming activity, but also are involved in the development of
malignancy in vivo. The mutations at position 12 in the transforming genes of the EJ
and Calu-1 lines are especially interesting in that the predicted substitutions of the
amino acids valine and cysteine for glycine would be expected to alter the helical
structure of the normal rasHa and rasKi proteins, respectively, reducing their flexibility
and presumably altering their function. It is also noteworthy that in the EJ cell line
there is no amplification of the transforming gene and the amount of p21 ras protein
synthesized is not significantly increased [26,32,33]. Thus, if the activated rasHa gene
was involved in the development of the EJ bladder carcinoma, it was the qualitative
alteration rather than increased quantity of the protein that was critical.
Recently, Dhar and colleagues and we [unpublished results] have probed the
structure of the eleventh and twelfth codons of the rasHa gene in 15 bladder car-
cinomas and peripheral leukocytes from 35 normal individuals. We were able to do
this by direct Southern blotting since the normal sequence at this site, GCCGGC, is
recognized and cleaved by the enzymes Hpa II and Msp I, whereas sequences with
mutations in the CCGG tetranucleotide are resistant to these enzymes. All samples
contained the normal sequence in the first two positions of the twelfth codon. Thus,
mutations in the codon for amino acid 12 of the rasHa gene are not essential for the
development of bladder carcinoma and occur fairly infrequently.
A final transforming gene sequenced is one derived from a chicken B cell lym-
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phoma induced by ALV [37]. It is unrelated to the oncogene of any known virus and
has been designated Blym. From its sequence Blym codes for a protein of about 65
amino acids with significant homology to transferrin. This is of great interest since
transferrin is a mitogen and a requirement for many cells growing in serum-free
medium, and its level and that of its membrane-associated receptor are increased in
proliferating normal and tumor cells. Blym is also of potential importance for
human malignancy since at least certain murine and human lymphoid neoplasms
contain similar, if not identical, stage-specific transforming genes [20].
KARYOTYPIC ABNORMALITIES AT ONCOGENE LOCI
It has been known for some time that specific chromosomal abnormalities exist in
certain human malignancies. These include translocations in certain hematological
malignancies (e.g., BL, AML, APL, CML, and ALL) and deletions in certain solid
tumors and hematological malignancies (e.g., ovarian carcinoma, Wilm's tumor,
meningioma, and ALL). Until recently, the significance of these abnormalities was
unknown. However, many of the human genes related to viral oncogenes have been
localized to specific chromosomes (rasN, rasHa, and rasKi to chromosomes 1,11, and
12 [38-41], respectively; myb to chromosome 6 [42]; mos [43] and myc [43-45] to
chromosome 8; abl to chromosome 9 [46]; fes to chromosome 15 [46]; src to
chromosome 20 [47]; and sis to chromosome 22 [48]) and striking correlations have
been noted between the localizations of certain of the oncogenes and the sites of
breakage of chromosomes involved in specific translocations and deletions. More-
over, in two cases, entire oncogenes are translocated to new sites. The following
summarizes our current knowledge of several of these translocations and deletions.
Reciprocal translocations involving chromosome 22 (the Philadelphia chromo-
some) and chromosomes 9, 12, 17, or 19 are present in malignant cells in approxi-
mately 90 percent of patients with CML. The 9;22 translocation is most common. In
most cases of the 9;22 translocation examined to date, the breakpoint in chromo-
some 9 lies within band q34 [49] (q refers to the long arm and p to the short arm of
each chromosome), the site of the abi gene. Moreover, in at least certain cases the
translocation involves transfer of the entire abl gene to band qI 1 on chromosome 22
[50]. To date, no gene has been assigned to band ql 1; in fact, only one known on-
cogene, sis, has been identified on chromosome 22 and its location is not known.
Since chromosome 22 is the common denominator in all the translocations in CML
and since the clinical picture is essentially the same in patients with the 9; 12; 17; and
19;22 translocations, future efforts must be directed toward examination of the
structure and expression of genes located on chromosome 22, especially abl and sis.
Three translocations (2;8, 14;8, and 22;8) have been identified in both African
and non-African BL cell lines and in certain cases of ALL. The 14;8 translocation is
most common in BL and has been studied most extensively. Asnoted, chromosome
8 harbors two oncogenic genes, myc and mos, at bands q24 and q22 [43-451, respec-
tively. Although no oncogene has been assigned to chromosome 14, this chromo-
some does contain the gene for the immunoglobulin heavy chain mu at band q32
[51]. In certain BL lines, myc sequences have been identified on chromosome 14 at
q32 adjacent to mu heavy chain sequences [44,45], and mu sequences have been
found on chromosome 8 [45]. Thus, the translocation is reciprocal. Although the
significance of this translocation in BL is not clear, it is noteworthy that analogous
translocations involving myc and immunoglobulin genes occur in mouse plasmacy-
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tomas [53,54] and may be increased in certain BL lines [55,56].
The final translocation of interest is an 8;21 translocation seen in certain patients
with AML. The breakpoint on chromosome 8 in this translocation lies at band q22
[43] containing the mos gene. However, it is not known whether the mos gene re-
mains on chromosome 8 or is transferred to chromosome 21. It is also not known
whether mos expression is turned on.
Two deletions are of interest, involving, respectively, the rasHa gene located at
band p13 of chromosome 11 [40] and the myb gene located at band q24 of
chromosome 6 [42]. The former is important because individuals who lack p13 are
aniridic and are at risk to develop Wilm's tumor [57]. In addition, one patient with
Wilm's tumor has been identified with a deletion of p13 in tumor cells, but a normal
chromosome in other tissues [58]. The second deletion occurs in about 6 percent
of patients with ALL and involves loss of bands q21 to q25 of chromosome 6 [59],
including the myb gene. Alteration of rasHa and myb expression in Wilm's tumor and
ALL, respectively, has not been reported.
Although correlations between the chromosomal locations of oncogenes and
breakpoints in translocations and deletions in the aforementioned malignancies are
striking, there are no data yet which directly demonstrate that the indicated on-
cogenes play a role in the development of the cited malignancies. However, two
mechanisms by which translocations may result in malignancy seem plausible. On
the one hand, an oncogene may undergo an alteration in sequence during transloca-
tion possibly resulting in altered function and malignancy. Alternatively, as has been
shown for ALV-induced lymphomas of chickens [60], translocation of an oncogene
to a new location or insertion of a new DNA sequence adjacent to an oncogene may
bring the oncogene under the control of proximate strong promoter or activator se-
quences leading to increased expression and possibly to malignancy.
MULTIPLE ONCOGENIC HITS IN
THE DEVELOPMENT OF MALIGNANCY
Multiple hit theories of malignancy have been based on the observation that cer-
tain agents induce malignancies whereas others promote induction and on the need
to invoke one or more environmental events as well as one inherited mutation in the
etiology of familial malignancies. There is now accumulating evidence at the
molecular level which also suggests that multiple events are involved in the genesis of
certain malignancies.
For the HL60 APL cell line, current data suggest that at least two steps were in-
volved in the leukemogenic process: one step involving therasN transforming gene
[31] and a second step involving amplification and enhanced expression of the
cellular myc gene [61]. Amplified myc sequences have been identified not only in
cultured HL60 cells, but also in leukemic cells obtained directly from the patient.
Thus, amplification did not develop as a by-product of long-term culture.
Amplification of myc sequences has not yet been demonstrated in other myeloid
leukemias and so it may be restricted to APL or rare patients like the HL60 patient.
A second malignancy which seemingly results from multiple oncogenic hits is BL.
Current evidence suggests three oncogenic events: infection by EB virus [10], a
subsequent event involving the raSN transforming gene [31], and, likely, a third
event associated with the translocation of myc to chromosome 14 [44,45]. Finally, in
the human pre-B cell leukemia line SMS-SB, both vigorous expression of the cellular
abi gene and a transforming gene distinct from abi have been implicated [62].
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The apparent involvement of multiple steps in the malignant process in these
malignancies resembles that described in certain B cell lymphomas of chickens. At
least three steps appear to be important in development ofthis malignancy: infection
with ALV, integration of the ALV provirus immediately upstream of the cellular
myc gene and downstream promotion of myc expression [60], and some action of
the Blym transforming gene [37].
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